Continuous use of GLP-1 receptor agonists in adults with type 2 diabetes was associated with a lower risk of major ...

Novo Nordisk India chief says GLP-1 adoption remains low and the market untapped despite patent expiry opening it to generics ...

The therapy shows efficacy in improving diarrhea, abdominal pain in GLP-1, GLP-1/GIP-treated patients with diabetes and/or obesity in a small study.

A new study suggests heart health gains disappear in half the time it takes to build them up when people stop taking GLP-1 ...

Good outcomes relative to bariatric surgery after catheter ablation in observational data ...

Stopping GLP-1 medications is linked to a higher risk of heart attack, stroke, and death. Recent research found that even ...

As GLP-1 pills for weight loss enter the U.S. market, some pharmaceutical companies are testing the possibility of a gene therapy to stimulate GLP-1 production, The Washington Post reported Jan. 24.

Mt Baker Medical is excited to unveil its newly developed physician-supervised GLP-1 weight loss initiative, aimed at delivering safe and effective solutions for medical weight management. This ...

Researchers have found that adults who stop taking GLP-1 receptor agonist drugs such as semaglutide and tirzepatide face a measurable increase in heart attack, stroke, and death risk within months of ...

A new study suggests that almost half of people stopping GLP-1 weight-loss drugs may keep the weight off. However, many of these people continued other forms of treatment after stopping GLP-1 drugs.

Following a rapid increase in popularity of GLP-1 drugs for diabetes and weight loss, such as semaglutide and tirzepatide, ...

Dual therapy with a GLP-1 receptor agonist plus ixekizumab demonstrates long-term benefits in psoriatic disease activity, ...